Theoretically, even though the tax will have a major negative initial impact on Medical Device companies, it will end up generating more business, due to the increased patient population having access to healthcare, and having procedures which require the use of medical devices. However, that is not likely to happen.
At LSO, we typically manage 50-55 new product launches a year. This doesn’t include helping existing customers with product revisions and follow on work. This is a launch rate that far surpasses that of many multi-billion dollar medical device companies. Our volume is driven by our focus on the start-up market and our willingness to […]
So how do you publish an article from the client’s perspective, without breaking any non-disclosure agreements? Well you find yourself an ex-client which has been acquired for $1.5 billion, and have them tell you about their experience working with LSO. We are lucky that one such former client now works with us here at LSO. […]
Most medical device companies have product returns which are biohazardous. Some of these returns are biohazardous because hospitals didn’t follow their internal procedures, some are products that would have been disposed off by the hospital, but due to an issue in surgery they must be returned to the manufacturer, and some products are intended for reuse but must go through